MeSH tree: D12.644.400.300.001
By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not ...
Apr 10, 2026
0
781
Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first ...
Apr 9, 2026
0
6
Federal regulators on Wednesday approved Eli Lilly's new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.
Apr 1, 2026
0
11
An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in blood sugar and weight ...
Mar 30, 2026
0
2
Whether they're using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health.
Mar 23, 2026
0
3
A deluge of weight-loss drugs is set to transform the global fight against obesity as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent expired Friday.
Mar 20, 2026
0
9
Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular ...
Mar 18, 2026
0
25
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing ...
Mar 13, 2026
0
20
Patients without diabetes who switched GLP-1 receptor agonist (GLP-1RA) drugs for overweight or obesity were more likely to stick with their treatment longer than those who didn't switch, according to a new study by UT Southwestern ...
Mar 10, 2026
0
16
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published ...
Mar 10, 2026
0
73
